Status:

COMPLETED

COPD on Primary Care Treatment (COOPT)

Lead Sponsor:

Radboud University Medical Center

Collaborating Sponsors:

Dutch Health Care Insurance Board (CVZ)

GlaxoSmithKline

Conditions:

Pulmonary Disease, Chronic Obstructive

Lung Diseases, Obstructive

Eligibility:

All Genders

30-75 years

Phase:

PHASE4

Brief Summary

The aim of this family practice based study is to determine the long-term treatment effects of two drugs that are presumed to modify the course and progression of chronic obstructive pulmonary disease...

Detailed Description

Chronic obstructive pulmonary disease (COPD) is a disorder characterised by symptoms and abnormal tests of expiratory flow that do not change markedly over periods of several months observation. COPD ...

Eligibility Criteria

Inclusion

  • age between 30 and 75 years
  • being a smoker or ex-smoker
  • post-bronchodilator FEV1/FVC ratio is \<88% of the predicted value in case of men or \<89% of the predicted value in case of women
  • post-bronchodilator FEV1\>=40% and \<90% of the predicted value
  • subjects have a GP diagnosis of COPD or had increased cough, sputum and/or dyspnea on most days for 3 or more months a year, for at least the last 2 years
  • able to provide a written informed consent
  • expected to be able to comply with the study protocol
  • able to communicate with the study personnel and to understand and read instructions
  • females of childbearing potential should use an acceptable method for birth control

Exclusion

  • a known history of intolerance or allergy for N-acetylcysteine or fluticason
  • use of long-term oxygen therapy or expected to be in need of oxygen therapy within the next 3 years
  • registered asthma, allergic rhinitis, and/or allergic eczema as an active problem in the GPs records within the last 12 months
  • alpha1-antitrypsin deficiency
  • cystic fibrosis
  • active infection due to Mycobacterium tuberculosis
  • status post-lobectomy
  • clinically proven gastric or duodenal ulcer in the previous six months
  • non-compensated severe chronic congestive heart failure
  • life expectancy reduction (e.g. malignancies)
  • evidence of illicit drug use or abuse of alcohol intake
  • expected not to be compliant in taking medications in general
  • being pregnant or giving breastfeeding
  • not complying with the inclusion criteria

Key Trial Info

Start Date :

December 1 1998

Trial Type :

INTERVENTIONAL

End Date :

January 1 2003

Estimated Enrollment :

270 Patients enrolled

Trial Details

Trial ID

NCT00184977

Start Date

December 1 1998

End Date

January 1 2003

Last Update

March 12 2010

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Department of Family Medicine, University of Maastricht

Maastricht, Netherlands, 6200 MD

2

Department of Family Medicine, Radboud University Nijmegen Medical Centre

Nijmegen, Netherlands, 6500 HB